Been screening small caps outside the usual AI and biotech noise, and some of these overlooked financial plays are starting to look more interesting than I expected. One I stumbled on is TROO, the mix of lending, asset exposure, and fintech angle is unusual for something this small. Not saying it’s a guaranteed winner, just feels like one of those names people ignore until movement starts.
Herbal Dispatch announced today that it is accelerating its U.S. market plans in response to the U.S. HHS recommendation to move cannabis from Schedule I to Schedule III. This potential reclassification, if finalized by the DEA, would remove the Section 280E tax burden, improve access to banking and institutional capital, and support broader industry growth.
Key points from the update:
The company has built a solid base in Canada through its craft cannabis e-commerce platform and continues to focus on growth there while preparing for U.S. opportunities. This looks like a measured approach to position for potential regulatory changes. Worth watching if you're following cannabis stocks. What are your thoughts on this one?
Anyone following $HERB / $LUFFF?
I’ve been looking for some diamonds in the rough that should hopefully have a nice return on investment. I’ve settled on two plays, one is a lotto ticket and one seems like it should hopefully be a safe play.
So my case for FBIO… current market cap of 80 million, however expecting to receive over 100 million in proceeds from the sale of the PRV by Cyprium. On top of that they have several new FDA approvals. A rosacea drug that has expanding coverage among others. The market cap and the growth rate of the company do not make sense when they will have over 100 million in cash and a growing pipeline.
Now for the lotto ticket, BCTX. They have been working on a cancer vaccine for several years. Anyone who has invested in them previously probably has felt the pain of the drop. However, we are currently in a phase 3 trial for a CANCER VACCINE that has been ongoing for about a year with potential fast track approval from the government. It’s the most advanced treatment among others even when quoting pubmed. A little about this trial, the endpoint is overall survival in metastatic (stage 4) breast cancer compared to physicians treatment of choice. Considering overall survival takes some time to judge and that we have an earnings call coming up in mid June… if the news are positive we have endless room to run up. Currently valued with a market cap of 20 million.
Elon Musk, Tesla and SpaceX CEO
Jensen Huang, Nvidia CEO
Tim Cook, Apple CEO
Larry Fink, BlackRock CEO
Stephen Schwarzman, Blackstone CEO
Kelly Ortberg, Boeing CEO
Brian Sikes, Cargill CEO
Jane Fraser, Citigroup CEO
Larry Culp, General Electric CEO
David Solomon, Goldman Sachs CEO
Sanjay Mehrotra, Micron CEO
Cristiano Amon, Qualcomm CEO
President Trump also says there are "many other" CEOs joining him on the trip who have not yet been disclosed.
OceanPowerTechnologies ($OPTT) is listed on the SOF Week 2026 live demonstration schedule in Tampa, May 18–21.
SOF Week is focused on special operations, unmanned systems, autonomy, maritime robotics, sensors, and defense technology exactly the lane OPTT has been moving into with PowerBuoy, WAM-V, MERROWS, and marine robotics services.
With a single-day unrealized gain of $170,000, the total assets in my core account have officially crossed the $6.1 million threshold.
Back in 2015, when I transferred my initial seed capital of $80,211.39 into this account, I set this precise long-term goal in my mind. Today, at the age of 35, I officially declare: I am officially calling it quits today. The goal has been achieved; I am bidding a definitive farewell to any form of active daily trading or management, entrusting the growth of my wealth entirely to the "Owner's Earnings" generated by these great enterprises.
I know that when many people look at this chart, their eyes will fixate solely on NVDA—specifically its nearly 300% return and the unrealized gain of over $1 million on that single stock—or perhaps on the multi-bagger profits from TSM and MU. Most people will attribute this success to "good luck—winning a bet on the AI sector."
They couldn't be more wrong.
As an allocator of "Rational Capital," I never pay a premium for nebulous, intangible "concepts." I took heavy positions in these computing power and semiconductor infrastructure providers not because the news cycle was screaming about AI every day, but because I had peeled back the layers of the 10-K financial reports filed by the major tech giants.
While the market was still caught up in speculative sentiment, I saw only the coldest, hardest business logic: downstream industry giants, desperate to defend their competitive moats, were compelled to engage in a defensive CapEx (Capital Expenditure) arms race of staggering magnitude. And these massive expenditures—totaling in the hundreds of billions—would, without a shadow of a doubt, ultimately translate into tangible Free Cash Flow on the balance sheets of NVDA and TSM. This represents the pinnacle of monopolistic pricing power—the only form of intrinsic value truly worthy of my capital allocation.
The journey from $80,000 to $6 million was an incredibly monotonous one. There was no frequent portfolio turnover, no day trading—only a dogged focus on underlying business fundamentals, a patient wait for prices to dip within a safe margin of safety, and then—acting like a true "Business Owner"—a complete disregard for all macroeconomic noise and jagged market volatility. Once you grasp the divergence between price and value, investing becomes an exceedingly tedious—yet inevitably victorious—game.
To my fellow travelers in this circle who truly understand financial modeling and manage real capital: I will see you at the summit.
Just 3 months ago, Nicholas Woodhams added $OPTT (Ocean Power Technologies) to his advisory portfolio.
There was no announcement of this role and for an advisor role, that’s completely normal (no press release or 8-K is required).
But the better question is: why would anyone care what three companies he advises at the same time?
Because he is currently listed as an active advisor to all three:
• Kestrel Global Ltd. (since January 2026)
• Adtingo Agritech (since May 2023)
• $OPTT (since March 2026)
The Kestrel Global connection is the one that really stands out.
Kestrel Global is the Dubai based strategic advisory firm run by Harry A H Amos.
Harry has spent over a decade building elite access across the UAE/GCC royal family patronage (including work under HH Sheikh Mohammed bin Rashid Al Maktoum), direct relationships with Crown Princes and Rulers, senior government ministers, and sovereign wealth funds. His background as a British Army Captain with Sandhurst training and operational tours adds serious credibility in defense and critical infrastructure circles.
They specialize in high level royal family access, government introductions, and market entry deals for Western tech companies in the UAE/GCC.
Public Kestrel materials reference work or support involving major names like $TSLA, $JOBY, Huspy, what3words, Oxford Flow, Boom Supersonic, Fresh To Home, Aleph Farms, SparkCognition, and others.
$OPTT is already actively expanding in the UAE through partnerships with Remah International Group and Unique Group.
That does not prove any new deal, contract, or formal partnership.
But it does create a very interesting, publicly visible advisory bridge between $OPTT and the exact firm (and the exact person) that opens elite GCC doors for companies like Tesla and Joby.
Tickers: $OPTT $TSLA $JOBY
*Do your own research.
*This is not investment advice.
Side note:
Sorry for the delay!
If you’re into digging into early stage companies that aren’t getting much mainstream attention yet, this is exactly the kind of work I’m passionate about. Feel free to join r/OPTTbigbag and follow my account if you want more of it.
— u/Puzzled-Zucchini-556 • r/OPTTbigbag
Alpha Cognition (NASDAQ: ACOG $5.95 +0.46) MCAP: ~$130M
This afternoon's call won’t be defined by the headline revenue number. Investors already understand that revenues are likely to continue to be modest this quarter given the current payer environment and the slow-moving nature of LTC adoption:
The bigger question now is whether the underlying commercial engine is continuing to strengthen beneath the surface.
Here’s what sophisticated observers will be listening for:
I. LTC Density / Scripts-Per-Facility Growth
This is the single most important metric right now. Are facilities still mostly trialing ZUNVEYL with just 1–2 patients, or are early adopter homes beginning to expand utilization to 4+ patients per facility?
That distinction matters enormously. If facilities organically increase patient counts after initial trialing, the economics and long-term trajectory change dramatically.
That transition from isolated trial usage to broader embedded utilization is what ultimately determines whether the LTC model can scale economically.
II. Real PBM #2 Pull-Through
The contract is signed — now the market needs proof it’s actually translating into smoother commercial execution on the ground.
What investors should really be listening for is whether the downstream implementation process is beginning to materially improve the prescribing experience for LTC facilities and physicians. That could include:
The key issue is that many LTC facilities appear willing to trial ZUNVEYL on a small number of patients, but broad facility-level adoption becomes much harder when staff are forced to constantly navigate paperwork, appeals, and payer friction for every prescription.
If management can show that access friction is gradually easing, it increases the probability that facilities move from isolated “test patients” toward broader utilization across multiple residents.
Even incremental signs of progress here would be important because payer access — more than physician interest — may ultimately become the main factor determining how quickly the LTC adoption curve can scale.
III. Behavioral & Operational Signals Becoming Systematic + Payer Relevance
The next phase of the story likely depends on translating strong tolerability into measurable operational and economic relevance.
We want to hear whether management is seeing recurring trends around behavioral stabilization, agitation/anxiety reduction, antipsychotic use, falls/fractures, polypharmacy, or staffing burden in the BEACON, RESOLVE, and CONVERGE studies — and concrete timelines for when these datasets will actually mature and begin informing payer conversations.
If payer friction remains a major hurdle, we also want to hear how management plans to strengthen the real-world evidence package supporting ZUNVEYL’s value proposition in LTC.
That could include broader discussion around:
Even a hint from ACI that they plan to expand opportunities to generate real-world economic evidence for payers would be a major development.
IV. Subtle Economic / Total Cost of Care Framing
The April Cochrane review put a spotlight on what it described as the “trivial” real-world benefits of anti-amyloid therapies, leaving a void for practical, stabilizing therapies.
Any language from management pivoting toward “total cost of care,” downstream medical events, or facility-level economics will prove they are actively capitalizing on this macro shift to strengthen its long-term payer positioning.
V. Cash Burn & Runway Discipline
With a slow-building commercial ramp, disciplined capital allocation is critical. The company is investing heavily in LTC infrastructure, facility education, payer navigation, and multiple ongoing studies while revenue is still early in its scaling phase.
What investors will want reassurance on tomorrow is that management views the current balance sheet as sufficient to comfortably bridge the company through the key 2026/2027 commercialization and payer-inflection period without the need for a near-term, highly dilutive capital raise.
The market can tolerate a gradual ramp if it sees:
VI. Conclusion
Last quarter delivered several encouraging signals beneath the surface: strong facility reorder rates (~83%), continued expansion into new LTC homes, growing institutional ownership, and consistent real-world feedback on tolerability, behavior, and persistence.
The challenge is that these early positives have not yet translated into the accelerating revenue trajectory the market is looking for — especially given the current commercial spend and lingering payer friction. That’s why tomorrow’s call is important.
The market doesn’t need a blowout quarter. What we're hoping for is clear evidence that the adoption curve is steepening: that early adopter facilities are deepening utilization (moving from 1–2 to 4+ patients), that PBM #2 is starting to reduce real-world friction, and that management is beginning to articulate a broader operational and economic value story for ZUNVEYL in LTC.
If we see continued progress on those fronts — even with modest headline revenue — confidence in the long-term commercialization path will rise meaningfully.
Posted on behalf of Luca Mining Corp. - (TSX-V: LUCA) CEO Dan Barnholden joined VSA Capital’s Ollie O’Donnell to discuss FY25 results, Q1 2026 production, and the roadmap through 2027.
Setting the Stage
Luca marks one year as a multi-mine operator, with FY25 and Q1/26 results underscoring a material financial turnaround
FY25 Transformation vs FY23
• Q4 generated >US$20M in free cash flow
• FY25 year-end cash: ~US$25.5M
• Q1 2026 cash: ~US$36.5M
• Debt reduced from ~US$30M (FY23) to ~US$1.4M, with full repayment expected this quarter
A near mirror-image balance sheet shift in two years.
Exploration Through 2027
• US$7.5M drill budget in 2026
• Three-year, US$25M exploration plan
• Six rigs turning across both assets
• Silver stream expected to materially reduce by late 2027/early 2028, unlocking incremental cash flow
Debt-Free & Cash Accretive
Management emphasizes cash growth as the core performance metric — with no equity raise on the horizon
Share Price vs Commodity Leverage
Despite zinc, copper, gold, and silver strength, management believes LUCA’s operational cash generation is not yet reflected in the share price
Accounting Loss vs Operational Profitability
The reported net loss was largely driven by accounting treatment of the silver stream. Operationally, Tahuehueto remains cash generative, with ~700,000 oz remaining on the stream
Shareholder Value Actions
A structured silver call strategy in Q1 crystallized >US$3M in gains, directly enhancing the cash balance
Cost Optimization:
Tahuehueto
• New COO appointed
• Throughput record: 1,350 tpd (nameplate 1,200 tpd)
• Improving grade consistency (~4 g/t AuEq)
• Near-mine higher-grade intercepts identified
Cost Optimization: Campo Morado
• Metallurgical recovery improvements underway
• New PhD metallurgist hired
• Expansion study targeting improved gold and silver recovery in H2 2026
Exploration Acceleration
Six drills turning across both mines aim to extend mine life, grow resources, and potentially improve grade profiles
Newsflow Through 2027
2026 focus:
• Aggressive exploration
• Campo Morado expansion initiatives
• Ongoing cash growth
• Active M&A targeting a potential third asset
FY25 repositioned Luca from leveraged developer to cash-generating multi-asset producer. With debt nearly eliminated, exploration fully funded, cost optimization underway, and silver stream relief approaching by 2027, management is focused on compounding cash flow and expanding the platform.
$MWYN News April 23, 2026
MWYN Announces Formation of New Subsidiary, NexaCore Technologies, to Expand AI Computing and Infrastructure Services
Astera Labs, Inc. (ALAB) isn’t really an “AI chip” company, it’s a data movement and orchestration bottleneck play. The market understands GPUs are important, but I don’t think it fully appreciates how insane the interconnect, memory coordination, rack-scale bandwidth, and infrastructure complexity problems become as AI scales into inference, agents, and persistent workloads. ALAB sits directly in the path of that buildout and could become a deeply embedded control layer inside next-generation AI infrastructure before the market fully prices how strategically important that role may become. The stock has rerated hard already, but if AI infrastructure continues evolving beyond the current training phase, there’s a real chance the market still doesn’t understand how large and durable the opportunity actually is. Disclaimer: I own ALAB. This is not investment advice. Edcuational purposes only. Do you own DD.
$CRDL News April 14, 2026
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart